ImmunoPrecise Antibodies Ltd. (IPA)
| Market Cap | 133.62M |
| Revenue (ttm) | 17.18M |
| Net Income (ttm) | n/a |
| Shares Out | 19.08M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $6.81 |
| Previous Close | $7.16 |
| Change ($) | -0.35 |
| Change (%) | -4.89% |
| Day's Open | 7.00 |
| Day's Range | 6.81 - 7.36 |
| Day's Volume | 64,822 |
| 52-Week Range | 6.64 - 33.34 |
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary Talem Therapeutics LLC has advanced developing a candidate referred to as TATX-112, against an undisclosed target, into formal lead candidate char...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery...
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) announces preliminary preclinical data of TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In the SARS-Co...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamster...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced ...
VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. ("Company" or "IPA") (TSXV: IPA) (Nasdaq: IPA), a leader in full-service, therapeutic antibody discovery and development, today...
VICTORIA, BC, Nov. 3, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and deve...
Developing Antibodies for Covid-19
Sep.28 -- Jennifer Bath, chief executive officer at Immunoprecise Antibodies Ltd., discusses the company's potentially groundbreaking Covid-19 antibody treatment on "Bloomberg Technology.
About IPA
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production an... [Read more...]
| Industry Biotechnology | IPO Date Jan 3, 2017 |
| Stock Exchange NASDAQ | Ticker Symbol IPA |
Financial Performance
In 2020, IPA's revenue was 14.06 million, an increase of 28.66% compared to the previous year's 10.93 million. Losses were -4.95 million, -35.05% less than in 2019.